News

Filter

Current filters:

None

28 to 37 of 97218 results

Amgen reveals Blincyto price as $178,000 per course

Amgen reveals Blincyto price as $178,000 per course

18-12-2014

USA-based Amgen has revealed its intended pricing for its immunotherapy Blincyto (blinatumomab), which…

AmgenBiotechnologyBlincytoOncologyPricingUSA

X-Chem licenses second cardiovascular drug discovery program to Bayer

X-Chem licenses second cardiovascular drug discovery program to Bayer

18-12-2014

Privately-held biotech firm X-Chem has licensed a second drug discovery program to German pharma major…

BayerBiotechnologyCardio-vascularLicensingX-Chem

Insulin therapeutics specialist Nutrinia completes $12 million financing round

Insulin therapeutics specialist Nutrinia completes $12 million financing round

18-12-2014

Nutrinia, a developer of oral insulin therapies to treat rare gastrointestinal disorders in babies, has…

Business FinanceEndocrine systemGastro-intestinalsNutriniaPharmaceutical

Eisai's Halaven now available in Russia for advanced breast cancer

Eisai's Halaven now available in Russia for advanced breast cancer

18-12-2014

Halaven (eribulin) manufactured by Japanese drug major Eisai is now available in Russia.

EisaiHalavenOncologyPharmaceuticalRegulationRussia

Lundbeck to stop further development of desmoteplase

Lundbeck to stop further development of desmoteplase

18-12-2014

Following evaluation of disappointing clinical results, Danish CNS specialists Lundbeck said late yesterday…

Cardio-vasculardesmoteplaseFinancialLundbeckNeurologicalPharmaceuticalResearch

Auspex leaps on positive results from Phase III trial of SD-809 in Huntington's chorea

Auspex leaps on positive results from Phase III trial of SD-809 in Huntington's chorea

17-12-2014

Movement disorder biopharma specialist Auspex Pharmaceuticals announced positive top-line data from its…

Auspex PharmaceuticalsNeurologicalPharmaceuticalResearchSD-809USA

28 to 37 of 97218 results

COMPANY SPOTLIGHT

Parexel

Parexel

Back to top